Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α.
- DOI
- 10.1002/ctm2.577
- Published
- 2021 Nov
- Container
- Clinical and translational medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/ctm2.577,
title = {Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α.},
author = {Chen Y and Zhang J and Zhang M and Song Y and Zhang Y and Fan S and Ren S and Fu L and Zhang N and Hui H and Shen X},
year = {2021},
journal = {Clinical and translational medicine},
doi = {10.1002/ctm2.577},
url = {https://doi.org/10.1002/ctm2.577}
}RIS
TY - JOUR TI - Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α. AU - Chen Y AU - Zhang J AU - Zhang M AU - Song Y AU - Zhang Y AU - Fan S AU - Ren S AU - Fu L AU - Zhang N AU - Hui H AU - Shen X PY - 2021 JO - Clinical and translational medicine DO - 10.1002/ctm2.577 UR - https://doi.org/10.1002/ctm2.577 ER -
APA
Y, C., J, Z., M, Z., Y, S., Y, Z., S, F., S, R., L, F., N, Z., H, H., & X, S. (2021). Baicalein resensitizes tamoxifen-resistant breast cancer cells by reducing aerobic glycolysis and reversing mitochondrial dysfunction via inhibition of hypoxia-inducible factor-1α.. Clinical and translational medicine. https://doi.org/10.1002/ctm2.577
Source records
- pubmed · retrieved 2026-09-25T13:26:28.542Z